Literature DB >> 9814956

Development of bivalent rgp120 vaccines to prevent HIV type 1 infection.

P W Berman1.   

Abstract

A new generation of "bivalent" gp120-based vaccines, effective against subtype B and subtype E viruses, has been developed. Antisera from rabbits and humans immunized with these vaccines are able to neutralize macrophage tropic and T-cell tropic viruses grown in activated peripheral blood mononuclear cells (PBMCs). These vaccines are now available for efficacy trials to determine the role of humoral immunity in providing protection against human immunodeficiency virus type 1 (HIV-1) infection.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9814956

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


  34 in total

Review 1.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Production of a recombinant monoclonal antibody to Herpes Simplex Virus glycoprotein D for immunoaffinity purification of tagged proteins.

Authors:  Sara M O'Rourke; Bin Yu; Javier F Morales; Chelsea M Didinger; David L Alexander; Christopher Vollmers; Phillip W Berman
Journal:  J Immunol Methods       Date:  2018-11-28       Impact factor: 2.303

3.  Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.

Authors:  Kening Wang; Georgia D Tomaras; Sinthujan Jegaskanda; M Anthony Moody; Hua-Xin Liao; Kyle N Goodman; Phillip W Berman; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayapan; Jaranit Kaewkungwal; Barton F Haynes; Jeffrey I Cohen
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

4.  Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion.

Authors:  S Munir Alam; Hua-Xin Liao; Georgia D Tomaras; Mattia Bonsignori; Chun-Yen Tsao; Kwan-Ki Hwang; Haiyan Chen; Krissey E Lloyd; Cindy Bowman; Laura Sutherland; Thomas L Jeffries; Daniel M Kozink; Shelley Stewart; Kara Anasti; Frederick H Jaeger; Robert Parks; Nicole L Yates; R Glenn Overman; Faruk Sinangil; Phillip W Berman; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Nicos Karasavva; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Susan Zolla-Pazner; Sampa Santra; Norman L Letvin; Stephen C Harrison; Barton F Haynes
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

5.  Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.

Authors:  Sara M O'Rourke; Becky Schweighardt; Pham Phung; Kathryn A Mesa; Aaron L Vollrath; Gwen P Tatsuno; Briana To; Faruk Sinangil; Kay Limoli; Terri Wrin; Phillip W Berman
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

6.  Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies.

Authors:  Douglas H Smith; Peggy Winters-Digiacinto; Misrach Mitiku; Sara O'Rourke; Faruk Sinangil; Terri Wrin; David C Montefiori; Phillip W Berman
Journal:  PLoS One       Date:  2010-08-11       Impact factor: 3.240

Review 7.  Sieve analysis in HIV-1 vaccine efficacy trials.

Authors:  Paul T Edlefsen; Peter B Gilbert; Morgane Rolland
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

8.  Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.

Authors:  Javier F Morales; Bin Yu; Gerardo Perez; Kathryn A Mesa; David L Alexander; Phillip W Berman
Journal:  Mol Immunol       Date:  2016-07-21       Impact factor: 4.407

9.  Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell Immunity.

Authors:  Blake F Frey; Jiansheng Jiang; Yongjun Sui; Lisa F Boyd; Bin Yu; Gwen Tatsuno; Rolf Billeskov; Shahram Solaymani-Mohammadi; Phillip W Berman; David H Margulies; Jay A Berzofsky
Journal:  J Immunol       Date:  2018-01-26       Impact factor: 5.422

10.  HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development.

Authors:  Mangala Rao; Kristina K Peachman; Jiae Kim; Guofen Gao; Carl R Alving; Nelson L Michael; Venigalla B Rao
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.